Clinical trials: AML
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Selinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial…
- Trial name
- NCT02416908
- Testing
- Selinexor, Cladribine, G-CSF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in…
- Trial name
- NCT00088218
- Testing
- Clofarabine, Ara-C
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- M.D. Anderson Cancer Center
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT06006403
- Testing
- CD123 targeted CAR-NK cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Leukemia, Myeloid, Acute
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine.
- Trial name
- NCT06384261
- Testing
- Cusatuzumab, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 140 people
- Sponsor
- OncoVerity, Inc.
Leukemia, Myeloid, Chronic, Lymphomas
Post Transplant Donor Lymphocyte Infusion
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00167180
- Testing
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
To evaluate the efficacy of PEG-BCT-100 in patients with relapsed or refractory acute myeloid leukemia (AML) in terms of remission rate.
- Trial name
- NCT02899286
- Testing
- PEG-BCT-100
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Bio-Cancer Treatment International Limited
Adult Acute Myeloid Leukemia
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T…
- Trial name
- NCT03114670
- Testing
- CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Acute Myeloid Leukemia
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.
- Trial name
- NCT04827069
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03630991
- Testing
- Edetate Calcium Disodium, Multivitamin, Succimer
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Acute Myeloid Leukemia(AML)
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Trial name
- NCT07233018
- Testing
- CT0991 CAR-T cells infusicn
- Where
- China
- Volunteers
- 24 people
- Sponsor
- MEI HENG
Acute Myeloid Leukemia
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
- Trial name
- NCT07303660
- Testing
- ZE50-0134, Azacitidine Days 1-7, ZE 50-0134
- Where
- 6 sites in Russia, Uzbekistan
- Volunteers
- 66 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML
Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT
This is a prospective, multicenter, cohort study. The high-risk, relapse and refractory AML patients were enrolled in this study.
- Trial name
- Donor chose (NCT06686173)
- Testing
- non-intervention study, donor selection
- Volunteers
- 114 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
- Trial name
- NCT00251368
- Testing
- 9-Aminocamptothecin (9-AC)
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia, Relapsed AML
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Relapsed AML, Refractory AML
- Trial name
- NCT03516760
- Testing
- GEM333
- Where
- 7 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AvenCell Europe GmbH
Acute Myeloid Leukemia, Adult
NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study
This prospective, single-center, randomized controlled clinical trial aims to evaluate whether N-acetyl-L-cysteine (NAC) can promote hematopoietic recovery after chemotherapy in patients with acute myeloid leukemia (AML), and to…
- Trial name
- 2026-07-06 (NCT07869342)
- Testing
- N-acetyl-L-cysteine (NAC)
- Volunteers
- 180 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
This randomized phase I trial is studying the side effects and best dose of vorinostat when given together with idarubicin in treating patients with relapsed or refractory leukemia or myelodysplastic syndromes.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00331513
- Testing
- vorinostat, idarubicin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center